Effect of new thiazolidine derivatives LPSF/GQ-02 and LPSF/GQ-16 on atherosclerotic lesions in LDL receptor-deficient mice (LDLR-/-)

Cardiovascular Pathology

Volumn 22, Issue 1, 2013, Pages 81-90

  Soares E Silva, Amanda Karolina ^a   De Oliveira Cipriano Torres, Dilênia ^a,b   Santos Rocha, Sura Wanessa ^a   Dos Santos Gomes, Fabiana Oliveira ^a   Dos Santos Silva, Bruna ^a   Donato, Mariana Aragão Matos ^a   Raposo, Catarina ^c   Santos, Ana Célia Oliveira ^b   De Lima, Maria Do Carmo Alves ^d   Galdino, Suely Lins ^d   Da Rocha Pitta, Ivan ^d   De Souza, José Roberto Botelho ^d   Peixoto, Christina Alves ^a,c  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^c Centro de Tecnologias Estrategicas Do Nordeste   (Brazil)

^d FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Atherosclerosis; New drugs; Thiazolidinediones

Indexed keywords

5 (4 BROMO 2 METHOXY BENZYLIDENE) 3 (4 METHYL BENZYL) THIAZOLIDINE-2,4 DIONE; GELATINASE B; GQ 02; GQ 16; LOW DENSITY LIPOPROTEIN RECEPTOR; PIOGLITAZONE; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; APOPTOSIS; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLOOD SAMPLING; CHEMICAL ANALYSIS; CONTROLLED STUDY; ENDOTHELIUM; FEEDING; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID DIET; MORPHOMETRICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SUBENDOTHELIUM;

ANIMALS; AORTA; AORTIC DISEASES; APOPTOSIS; ATHEROSCLEROSIS; BLOOD GLUCOSE; BLOTTING, WESTERN; CARDIOVASCULAR AGENTS; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; IMMUNOHISTOCHEMISTRY; INSULIN; INSULIN RESISTANCE; LIPIDS; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, ELECTRON, TRANSMISSION; NITRIC OXIDE SYNTHASE TYPE III; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, LDL; THIAZOLIDINEDIONES; THIAZOLIDINES; TIME FACTORS;

EID: 84870913060     PISSN: 10548807     EISSN: 18791336     Source Type: Journal    
DOI: 10.1016/j.carpath.2012.05.006     Document Type: Article

References (59)

1. X. Yang, L. Peterson, and R. Thieringer Identification and validation of genes affecting aortic lesions in mice J Clin Invest 120 2010 2414 2422
2. K.J. Mukamal, R.W. Nesto, and M.C. Cohen Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction Diabetes Care 24 2001 1422 1427 (Pubitemid 33716431)
3. G. Howard, D.H. O'leary, and D. Zaccaro Insulin sensitivity and atherosclerosis: the Insulin Resistance Atherosclerosis Study (IRAS) Investigators Circulation 93 1996 1809 1817
4. C. Weber, A. Zernecke, and P. Libby The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models Nature 8 2008 802 815
5. H. Yki-Jarvinen Thiazolidinediones N Engl J Med 351 11 2004 1106 1118
6. T.M. Willson, P.J. Brown, and D.D. Sternbach The PPARs: from orphan receptors to drug discovery J Med Chem 43 2000 527 550 (Pubitemid 30127149)
7. A.R. Collins, W.P. Meehan, and U. Kintscher Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice Arterioscler Thromb Vasc Biol 21 2001 365 371 (Pubitemid 32199117)
8. A.C. Li, K.K. Brown, and M.J. Silvestre Peroxisome proliferator-activated receptor ligands inhibit development of atherosclerosis in LDL receptor-deficient mice J Clin Invest 106 2000 523 531 (Pubitemid 30666385)
9. J. Minamikawa, S. Tanaka, and M. Yamauchi Potent inhibitory effects of troglitazone on carotid arterial wall thickness in type 2 diabetes J Clin Endocrinol Metab 83 1998 1818 1820 (Pubitemid 28501066)
10. M.R. Langenfeld, T. Forst, and C. Hohberg Pioglitazone decreases carotid íntima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study Circulation 111 19 2005 2525 2531 (Pubitemid 40696142)
11. J.S. Sidhu, Z. Kaposzta, and H.S. Markus Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus Arterioscler Thromb Vasc Biol 24 5 2004 930 934 (Pubitemid 38620874)
12. J.S. Sidhu, D. Cowan, and J.C. Kaski Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus Am J Cardiol 94 2 2004 151 156 (Pubitemid 38902860)
13. K. Chang, S.A. Francis, E. Aikawa, J.L. Figueiredo, R.H. Kohler, J.R. McCarthy, R. Weissleder, J. Plutzky, and F.A. Jaffer Pioglitazone suppresses inflammation in vivo in murine carotid atherosclerosis: novel detection by dual-target fluorescence molecular imaging Arterioscler Thromb Vasc Biol 30 2010 1933 1939
14. C.H. Wang, R.D. Weisel, and P.P. Liu Glitazones and heart failure: critical appraisal for the clinician Circulation 107 2003 1350 1354 (Pubitemid 36350730)
15. A.J. Scheen Thiazolidinediones and liver toxicity Diabetes Metab 27 2001 305 313 (Pubitemid 32625383)
16. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 24 2007 2457 2471 (Pubitemid 46919772)
17. J.A. Dormandy, B. Charbonnel, and D.J. Eckland Secondary prevention of macrovascular events in patients with type 2 diabetes in the Proactive Study (Prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial Lancet 366 2005 1279 1289 (Pubitemid 41416583)
18. R.H. Mourão, T.G. Silva, and A.L. Soares Synthesis and biological activity of novel acridinylidene and benzylidene thiazolidinediones Eur J Med Chem 40 2005 129 1133
19. C. Napoli, F. Nigris, and J.S. Welch Maternal hypercholesterolemia during pregnancy promotes early atherogenesis in LDL receptor-deficient mice and alters aortic gene expression determined by microarray Circulation 105 2002 1360 1367 (Pubitemid 34260429)
20. B.A. Game, L. He, and V. Jarido Pioglitazone inhibits connective tissue growth factor expression in advanced atherosclerotic plaques in low-density lipoprotein receptor-deficient mice Atherosclerosis 192 2007 85 91 (Pubitemid 46602308)
21. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 6 1972 499 502
22. R.K. Tangirala, E.M. Rubin, and W. Palinski Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesion between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice J Lipid Res 36 1995 2320 2328
23. M.A. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal Biochem 72 1970 240 254
24. C. Day Thiazolidinediones: a new class of antidiabetic drugs Diabet Med 16 3 1999 179 192
25. W.A. Hseuh, S. Jackson, and R.E. Law Control of cardiovascular cell proliferation and migration by PPARy, a new approach to the macrovascular complications of diabetes Diabetes Care 24 2001 392 397 (Pubitemid 32119143)
26. U. Kintscher, S. Goetze, and S. Wakino Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocytes chemotactic protein-1-direct migration of monocytes Eur J Pharmacol 401 3 2000 259 270 (Pubitemid 30608710)
27. P. Tontonoz, L. Nagy, and J.G. Alvarez PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL Cell 93 2 1998 241 252 (Pubitemid 28180857)
28. G. Chinetti, S. Lestavel, and V. Bocher PPARalpha and PPARgamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway Nat Med 7 1 2001 53 58 (Pubitemid 32095642)
29. N. Marx, U. Schönbeck, and M.A. Lazar Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells Circ Res 83 11 1998 1097 1103 (Pubitemid 28533518)
30. M. Rizzo, J. Kotur-Stevuljevic, and K. Berneis Atherogenic dyslipidemia and oxidative stress: a new look Transl Res 153 2009 217 223
31. H. Nakaya, B.D. Summers, and A.C. Nicholson Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARγ ligand pioglitazone Am J Pathol 174 2009 2007 2014
32. S. Saha, L.S. New, and H.K. Ho Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity Toxicol Lett 192 2010 141 149
33. V.K. Agarwal, J.G. Mchutchison, and J.H. Hoofnagle Important elements for the diagnosis of drug-induced liver injury Clin Gastroenterol Hepatol 8 2010 463 470
34. K. Pyrola, T.R. Pedersen, and J. Kjekshus Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care 20 4 1997 614 620 (Pubitemid 27143424)
35. R.A. Defronzo From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus [Banting Lecture] Diabetes 58 2009 773 795
36. H.S. Camp Thiazolidinediones in diabetes: current status and future outlook Curr Opin Investig Drugs 4 2003 406 411 (Pubitemid 36681625)
37. A.C. Kalkin, M.F. Josephine, and M. Craig Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects Arterioscler Thromb Vasc Biol 25 2005 1903 1909
38. M. Ricote, A.C. Li, and T.M. Willson The peroxisome proliferator- activated receptor-gamma is a negative regulator of macrophage activation Nature 391 1998 79 82 (Pubitemid 28079218)
39. M. Ishibashi, K. Egashira, and K. Hiasa Antiinflammatory and antiarteriosclerotic effects of pioglitazone Hypertension 40 5 2002 687 693 (Pubitemid 35282444)
40. M. Joner, A. Farb, and Q. Cheng Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1 Arterioscler Thromb Vasc Biol 27 1 2007 182 189 (Pubitemid 46360397)
41. E. Imamoto, N. Yoshida, and K. Uchiyama Inhibitory effect of pioglitazone on expression of adhesion molecules on neutrophils and endothelial cells Biofactors 20 1 2004 37 47 (Pubitemid 38586208)
42. N. Hennuyer, A. Tailleux, and G. Torpier PPARα, but not PPARγ, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia Arterioscler Thromb Vasc Biol 25 2005 1897 1902 (Pubitemid 41243460)
43. L.B. Kier, and L.H. Hall Bioisosterism: quantitation of structure and property effects Chem Biodivers 1 2004 138 151
44. I. Tabas Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis Arterioscler Thromb Vasc Biol 25 2005 2255 2264
45. E. Thorp, G. Kuriakose, and Y.M. Shah Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice Circulation 116 2007 2182 2190 (Pubitemid 350060356)
46. R. Joannides, W.E. Haefeli, L. Linder, and V. Richard Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo Circulation 92 1995 1314 1319
47. F. Kim, K.A. Tysseling, J. Rice, M. Pham, L. Haji, B.M. Gallis, A.S. Baas, P. Paramsothy, C.M. Giachelli, M.A. Corson, and E.W. Raines Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta Arterioscler Thromb Vasc Biol 25 5 2005 989 994 (Pubitemid 40627844)
48. T.J. Verbeuren, M.C. Coene, F.H. Jordaens, C.E. Van Hove, L.L. Zonnekeyn, and A.G. Herman Effect of hypercholesterolemia on vascular reactivity in the rabbit. II. Influence of treatment with dipyridamole on endothelium-dependent and endothelium-independent responses in isolated aortas of control and hypercholesterolemic rabbits Circ Res 1986 496 504 (Pubitemid 17000925)
49. M. Spiecker, H.B. Peng, and J.K. Liao Inhibition of endothelial vascular cell adhesion molecule-1 expression by nitric oxide involves the induction and nuclear translocation of IkappaBalpha J Biol Chem 272 49 1997 30969 30974 (Pubitemid 27527541)
50. T. Aizawa, H. Wei, J.M. Miano, J. Abe, B.C. Berk, and C. Yan Role of phosphodiesterase 3 in NO/cGMP-mediated antiinflammatory effects in vascular smooth muscle cells Circ Res 93 5 2003 406 413 (Pubitemid 37100005)
51. K. Goya, S. Sumitani, M. Otsuki, X. Xu, H. Yamamoto, S. Kurebayashi, H. Saito, H. Kouhara, and S. Kasayama The thiazolidinedione drug troglitazone up-regulates nitric oxide synthase expression in vascular endothelial cells J Diabetes Complications 20 5 2006 336 342 (Pubitemid 44292533)
52. Z.S. Galis, G.K. Sukhova, M.W. Lark, and P. Libby Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques J Clin Invest 94 1994 2493 2503 (Pubitemid 24379627)
53. I.M. Loftus, A.R. Naylor, P.R. Bell, and M.M. Thompson Matrix metalloproteinases and atherosclerotic plaque instability Br J Surg 89 2002 680 694 (Pubitemid 34595692)
54. A.K. Chow, J. Cena, and R. Schulz Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature Br J Pharmacol 152 2007 189 205 (Pubitemid 47517601)
55. I.M. Loftus, A.R. Naylor, S. Goodall, M. Crowther, L. Jones, and P.R. Bell Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption Stroke 31 2000 40 47 (Pubitemid 30035750)
56. 2 but not rosiglitazone regulates metalloproteinase 9, NOS-2, and cyclooxygenase 2 expression and functions by peroxisome proliferatory activated receptor +-dependent and -independent mechanisms in cardiac cells Shock 34 1 2010 60 67
57. R. Doležalová, Haluzík Mm, L. Bošanská , Z. Lacinová, Z. Kasalová, T. Štulc, and M. Haluzík Effect of PPAR-γ agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus Physiol Res 56 2007 741 748
58. R. Unal, A. Yao-Borengasser, V. Varma, N. Rasouli, C. Labbate, P.A. Kern, and G. Ranganathan Matrix metalloproteinase-9 is increased in obese subjects and decreases in response to pioglitazone J Clin Endocrinol Metab 95 2010 2993 3001
59. T. Shiomi, H. Tsutsui, S. Hayashidani, N. Suematsu, M. Ikeuchi, J. Wen, M. Ishibashi, T. Kubota, K. Egashira, and A. Takeshita Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction Circulation 106 2002 3126 3132 (Pubitemid 35440299)